Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of Health and Human Services? And how do you pronounce Journavx?
We discuss all that and more on this week's episode of "The Readout LOUD," STAT's biotech podcast. We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing. We also talk about the advancement of RFK Jr.'s nomination to be HHS secretary, the latest pharma earnings, and the approval of a non-opioid pain drug from Vertex Pharmaceuticals.
Listen Now
For more on the challenges in the CRISPR field, go here; to read more about RFK Jr.'s goals and challenges ahead, go here; and to learn more on Vertex's approval, go here.
Subscribe to the podcast on Apple Podcasts or Spotify to never miss an episode
Visit the archive to see past episodes
No comments